ReShape Lifesciences Inc. (RSLS) Financial Statements (2025 and earlier)

Company Profile

Business Address 1001 CALLE AMANECER
SAN CLEMENTE, CA 92673
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4,4593,85522,7653,90514,05523,735
Cash and cash equivalent4,4593,85522,7653,90514,05521,187
Short-term investments      2,548
Receivables1,700(410)(1,172)3,150285870
Inventory, net of allowances, customer advances and progress billings3,7413,6113,003 1,9361,580
Inventory3,7413,6113,003 1,9361,580
Prepaid expense19878736   
Other current assets126841883,9301,9592,462
Other undisclosed current assets722,6934,735(3,150)  
Total current assets:10,2969,91130,2557,83518,23528,647
Noncurrent Assets
Operating lease, right-of-use asset2501712665211,077
Property, plant and equipment606981,4549571,0811,739
Long-term investments and receivables  (100)    
Accounts and financing receivable, after allowance for credit loss  (100)    
Intangible assets, net (including goodwill)  26020,827   
Intangible assets, net (excluding goodwill)  26020,827   
Deferred income tax assets2856   
Other noncurrent assets29461,456   
Other undisclosed noncurrent assets  100 1,304  
Total noncurrent assets:3671,23124,0032,7822,1581,739
TOTAL ASSETS:10,66311,14254,25810,61720,39330,386
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3,5036,9666,6376801,4684,964
Employee-related liabilities 658203,805
Accounts payable1,6891,9263,4686156481,159
Accrued liabilities1,8145,0403,169   
Deferred revenue     424
Debt     5619,930
Other liabilities    3,8021,5241,985
Other undisclosed current liabilities274515694564 352
Total current liabilities:3,7777,4817,3315,0463,97717,231
Noncurrent Liabilities
Long-term debt and lease obligation    868567 
Long-term debt, excluding current maturities    430  
Liabilities, other than long-term debt151 55538 48
Deferred rent credit      48
Deferred income tax liabilities   555  
Other liabilities    38  
Operating lease, liability151  438567
Other undisclosed noncurrent liabilities72 300   
Total noncurrent liabilities:223 85590656748
Total liabilities:4,0007,4818,1865,9524,54417,279
Equity
Equity, attributable to parent6,6633,66146,0724,66515,84913,107
Common stock 231188823
Additional paid in capital642,302627,935622,906189,421188,271161,838
Accumulated other comprehensive loss(88)(88)(92)   
Accumulated deficit(635,574)(624,187)(576,760)(184,764)(172,430)(148,754)
Total equity:6,6633,66146,0724,66515,84913,107
TOTAL LIABILITIES AND EQUITY:10,66311,14254,25810,61720,39330,386

Income Statement (P&L) ($ in thousands)

9/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues8,67811,24013,6001,5883,2819,101
Cost of revenue(3,130)(4,438)(5,252)(1,004)(2,950)(5,423)
Cost of product and service sold(3,130)(4,438)(5,252)(1,004)  
Gross profit:5,5486,8028,3485843313,678
Operating expenses(20,931)(53,153)(64,849)(12,536)(23,561)(40,643)
Operating loss:(15,383)(46,351)(56,501)(11,952)(23,230)(36,965)
Nonoperating income (expense)144(130)168(411)(61)(189)
Gain (loss), foreign currency transaction, before tax22(141)168   
Other nonoperating income (expense)12211 (411)(61)(189)
Interest and debt expense  (2,061)   
Loss from continuing operations before equity method investments, income taxes:(15,239)(46,481)(58,394)(12,363)(23,291)(37,154)
Other undisclosed income (loss) from continuing operations before income taxes3,904(113)(3,645)   
Loss from continuing operations before income taxes:(11,335)(46,594)(62,039)(12,363)(23,291)(37,154)
Income tax expense (benefit)(52)380106   
Loss from continuing operations:(11,387)(46,214)(61,933)(12,363)(23,291)(37,154)
Loss before gain (loss) on sale of properties:(61,933)(12,363)(23,291)(37,154)
Net loss:(11,387)(46,214)(61,933)(12,363)(23,291)(37,154)
Other undisclosed net income (loss) attributable to parent    29(385)(226)
Net loss available to common stockholders, diluted:(11,387)(46,214)(61,933)(12,334)(23,676)(37,380)

Comprehensive Income ($ in thousands)

9/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(11,387)(46,214)(61,933)(12,363)(23,291)(37,154)
Other comprehensive income      5
Comprehensive loss:(11,387)(46,214)(61,933)(12,363)(23,291)(37,149)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent 42929(385)(226)
Comprehensive loss, net of tax, attributable to parent:(11,387)(46,210)(61,904)(12,334)(23,676)(37,375)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: